India, September 26, 2022: Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader announced that its India operations has become a signatory of the United Nations Global Compact (UNGC), the largest sustainability initiative globally.
As a signatory, Takeda has committed to adopting the Ten Principles of the UNGC which are derived from the Universal Declaration of Human Rights, the International Labour Organization’s Declaration on Fundamental Principles and Rights at Work, the Rio Declaration on Environment and Development, and the United Nations Convention Against Corruption.
Ratnesh Kumar, Executive Director, UN-GCNI said, “The commitment to support UNGC Principles & Sustainable Development Goals (SDGs) has encouraged socially responsible organizations to join the Global Compact initiative. We are delighted to welcome Takeda India into the GCN family and look forward to jointly pursuing goal-oriented initiatives towards the advancement of UN Global Compact’s mandates.”
Speaking on the announcement, Ms. Serina Fischer, General Manager for Takeda in India said, “Takeda is proud to have a values-based culture as its strong foundation. Our Global Code of Conduct is based on principles that are organized around Patient-Trust-Reputation-Business in that order. It embodies the spirit of Takeda — what we stand for and how we conduct ourselves. We are proud to become a signatory to adopt the Ten Principles of UNGC which is another step in bringing our global code of conduct to life and at the same time enables us in contributing to sustainable development goals (SDGs) while advocating for responsible business practices.”
“We’re focused on accelerating Environmental, Social, and Governance (ESG) initiatives across our business and look forward to working with the UNGC to make more progress toward the sustainable development goals (SDGs). Takeda in India is already a member of the UNGC’s Centre of Excellence for Governance, Ethics and Transparency (CEGET) and Anti-Corruption Collective Action Work Group (ACCA) focused on shaping governance transparency and anti-corruption initiatives” said Dr. Ruchi Sogarwal, Head of Public Affairs and Patient Advocacy for Takeda India.
Over the years, with its journey in India, Takeda has been a key industry leader in establishing ethical practices as a global corporate and is currently working to bring effective aid to rare disease patients in the country.
Ten Principles of the UNGC:
Principle 1: Businesses should support and respect the protection of internationally proclaimed human rights.
Principle 2: make sure that they are not complicit in human rights abuses.
Principle 3: Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining.
Principle 4: the elimination of all forms of forced and compulsory labour.
Principle 5: the effective abolition of child labour.
Principle 6: the elimination of discrimination in respect of employment and occupation.
Principle 7: Businesses should support a precautionary approach to environmental challenges.
Principle 8: undertake initiatives to promote greater environmental responsibility.
Principle 9: encourage the development and diffusion of environmentally friendly technologies.
Principle 10: Businesses should work against corruption in all its forms, including extortion and bribery.
About The United Nations Global Compact:
The UNGCN is the world’s largest corporate sustainability initiative having 14000+ companies, 3800+ non-business partners based on 169 countries. The UN Global Compact is a principle-based framework for businesses, stating ten principles in the areas of human rights, labor, the environment and anti-corruption. Under the Global Compact, companies are brought together with UN agencies, labor groups and civil society.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.